Can the elevated LDL, apolipoprotein B, and lipoprotein (a) levels be attributed to the IVF process itself?

Can IVF Itself Cause Elevated Lipid Levels?

Yes, IVF ovarian stimulation can transiently elevate lipoprotein(a) levels during the luteal phase, but this effect is temporary and related to high progesterone levels rather than the gonadotropins themselves—baseline dyslipidemia, however, is not caused by IVF and should be evaluated as a pre-existing cardiovascular risk factor.

The IVF-Related Lipid Changes

The ovarian stimulation process does produce measurable but temporary changes in Lp(a):

• During stimulated IVF cycles, Lp(a) concentrations increase significantly in the luteal phase 1
• This elevation is not due to FSH administration itself (whether recombinant or urinary FSH), but rather correlates with the high luteal progesterone concentrations that result from stimulation 1
• The increase is transitory—Lp(a) returns to baseline values within 1 month if pregnancy doesn't occur 1
• Women with low baseline Lp(a) (≤5 mg/dL) show greater increases than those with higher baseline levels 1

Critical distinction: Natural menstrual cycles show no significant changes in Lp(a) concentrations, confirming this is specific to the supraphysiologic hormonal environment of ovarian stimulation 1.

Pre-Existing Dyslipidemia vs. IVF Effects

The elevated LDL, apoB, and Lp(a) you're observing are more likely pre-existing conditions rather than IVF-induced changes:

Evidence that dyslipidemia affects IVF outcomes (not vice versa):

• Female dyslipidemia is associated with:

  • Longer stimulation duration and higher gonadotropin requirements
  • Lower 2PN fertilization rates
  • 4.5-fold higher odds of cumulative miscarriage (aOR = 4.455) 2
  • 67% lower odds of cumulative live birth (aOR = 0.335) 2

• Male dyslipidemia is associated with:

  • Fewer 2PN zygotes and transferable embryos
  • 69% lower odds of cumulative live birth (aOR = 0.309) 2

• Bilateral couple dyslipidemia shows:

  • 10.6-fold higher odds of miscarriage (aOR = 10.579) 2
  • 88% lower odds of live birth (aOR = 0.116) 2

Age and BMI modify these effects:

• In women <35 years: dyslipidemia reduces cumulative clinical pregnancy rate (aOR = 0.661) and live birth rate (aOR = 0.667) 3
• In women ≥35 years: dyslipidemia reduces oocyte retrieval rate (aOR = 0.954) 3
• In women with BMI ≥28: dyslipidemia reduces cleavage rate (aOR = 0.901) 3

Clinical Implications

Obtain baseline lipid screening before attributing elevations to IVF:

1. Lp(a) ≥50 mg/dL (≥125 nmol/L) should be considered a cardiovascular risk-enhancing factor 4
2. ApoB ≥130 mg/dL or non-HDL >190 mg/dL are also risk-enhancing factors 4
3. Lp(a) is genetically determined and unaffected by diet or most environmental factors—it should be measured once, ideally before fertility treatment 4

For PCOS patients specifically (a common IVF population):

• Up to 70% have dyslipidemia at diagnosis 4
• Higher Lp(a) concentrations occur especially in non-obese women with PCOS 4
• Screen with fasting lipids at PCOS diagnosis, before and during hormonal therapy 4

Common Pitfalls

• Don't dismiss elevated lipids as "just from IVF"—the transient luteal Lp(a) increase is modest and temporary, while persistent elevations indicate underlying dyslipidemia requiring cardiovascular risk assessment
• Don't wait until after IVF to screen—pre-existing dyslipidemia predicts worse reproductive outcomes and should be identified and managed beforehand
• Don't ignore male partner lipids—male dyslipidemia independently affects embryo quality and live birth rates 2